Deloitte's 10th Annual Accounting and Financial Reporting Update Offers Valuable Interpretive Guidance to Life Sciences Companies

News provided by

Mar 20, 2019, 10:10 ET

NEW YORK, March 20, 2019 /PRNewswire/ --

What:	2019 edition—and 10th annual—Deloitte Life Sciences Accounting and Financial Reporting Update

Who:	Jeff Ellis, U.S. audit & assurance leader, life sciences and health care, life sciences industry professional practice director, audit & assurance partner, Deloitte & Touche LLP Dennis Howell, senior consultation partner, accounting and reporting services, life sciences deputy industry professional practice director, audit & assurance partner, Deloitte & Touche LLP

When:	Available immediately

Audience:	Pharmaceutical manufacturers; biotechnology companies; medical device, diagnostic and medical equipment manufacturers; drug distributors; contract research organizations (CROs); contract manufacturing organizations (CMOs); and health technology companies.

Details:	Significant trends that could reshape the life sciences industry are unfolding in 2019, including the shift from treatment to wellness, pricing pressures, digital technology expansion, and increased use of real-world data and other advances in science. At the same time, finance and accounting professionals in the industry face complex issues and must exercise significant judgment in applying accounting rules and related interpretations affecting life sciences companies. In the 10th anniversary of the publication's launch, Deloitte's Life Sciences accounting and financial reporting update—including interpretive guidance report provides comprehensive guidance on how finance professionals can address these industry issues and trends. Large pharmaceutical companies, for example, can gain insights on how the new revenue recognition standard has been applied in practice, understand the emerging accounting for R&D funding arrangements and leases, and learn more about the upcoming changes to the PCAOB auditor's report. Biotech and emerging growth companies, including those in the evolving health tech sector, will appreciate the completely new chapter on initial public offerings and the updated guidance on accounting for collaborative arrangements. The 2019 Life Sciences accounting and financial reporting update offers in-depth insights on these and other emerging issues that can help life sciences financial professionals better navigate the accounting and reporting challenges they face.

About Deloitte
Deloitte provides industry-leading audit, consulting, tax and advisory services to many of the world's most admired brands, including nearly 90 percent of the Fortune 500 and more than 5,000 private and middle market companies. Our people work across the industry sectors that drive and shape today's marketplace to make an impact that matters — delivering measurable and lasting results that help reinforce public trust in our capital markets, inspire clients to see challenges as opportunities to transform and thrive, and help lead the way toward a stronger economy and a healthy society. Deloitte is proud to be part of the largest global professional services network serving our clients in the markets that are most important to them.

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee ("DTTL"), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as "Deloitte Global") does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the "Deloitte" name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.

SOURCE Deloitte